KRAS and neoplasm: In several preclinical lung cancer mouse models, treatment of KRAS-mutant lung adenocarcinoma (LUAD) with HG106 (a potent System Xc− inhibitor), significantly inhibited tumor growth and prolonged survival (Hu et al., 2020).